| 26.96 0.28 (1.05%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 35.36 | 1-year : | 38.38 |
| Resists | First : | 30.28 | Second : | 32.86 |
| Pivot price | 27.65  |
|||
| Supports | First : | 26.1 | Second : | 21.71 |
| MAs | MA(5) : | 26.78 |
MA(20) : | 28.2 |
| MA(100) : | 31.84 |
MA(250) : | 32.17 |
|
| MACD | MACD : | -1.2 |
Signal : | -1.1 |
| %K %D | K(14,3) : | 8.7 |
D(3) : | 8.1 |
| RSI | RSI(14): 38 |
|||
| 52-week | High : | 46.58 | Low : | 23.54 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SNWV ] has closed above bottom band by 35.3%. Bollinger Bands are 33.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 27.75 - 27.85 | 27.85 - 27.98 |
| Low: | 25.97 - 26.08 | 26.08 - 26.21 |
| Close: | 26.75 - 26.93 | 26.93 - 27.14 |
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.
Thu, 29 Jan 2026
SANUWAVE Health (OTCMKTS:SNWV) Shares Down 1% - Here's Why - MarketBeat
Tue, 27 Jan 2026
Sanuwave: A Compelling Asymmetric Opportunity In Advanced Wound Care - Seeking Alpha
Fri, 23 Jan 2026
SANUWAVE Health Inc (SNWV) Shares Gap Down to $26.58 on Jan 23 - GuruFocus
Wed, 14 Jan 2026
SANUWAVE Health, Inc. (NASDAQ:SNWV) Has Found A Path To Profitability - Yahoo Finance
Mon, 12 Jan 2026
Sanuwave Health (SNWV) Projects Significant Revenue Growth in Q4 2025 - GuruFocus
Fri, 09 Jan 2026
Sanuwave Health Q4 Preliminary Revenue Climbs - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 9 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 39.6 (%) |
| Shares Short | 427 (K) |
| Shares Short P.Month | 482 (K) |
| EPS | -0.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.35 |
| Profit Margin | -17.1 % |
| Operating Margin | 12.8 % |
| Return on Assets (ttm) | 14.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 22.2 % |
| Gross Profit (p.s.) | 3.76 |
| Sales Per Share | 4.81 |
| EBITDA (p.s.) | 0.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -36.94 |
| PEG Ratio | 0 |
| Price to Book value | -79.3 |
| Price to Sales | 5.6 |
| Price to Cash Flow | 177.93 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|